Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

The Influence of Finasteride on the Development of Prostate Cancer

Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen et al. · New England Journal of Medicine · 2003 · 2.5K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Peg Esper, Fei Mo, Gerald W. Chodak et al. · Urology · 1997 · 692 citations

Medicine, Oncology, Urology +16

Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical Progression

Richard Choo, Laurence Klotz, Cyril Danjoux et al. · The Journal of Urology · 2002 · 359 citations

Medicine, Oncology, Urology +17

CHEMOPREVENTION OF PROSTATE CANCER IN MEN AT HIGH RISK: RATIONALE AND DESIGN OF THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL

Gerald L. Andriole, David G. Bostwick, Otis W. Brawley et al. · The Journal of Urology · 2004 · 290 citations

Medicine, Pharmacology, Urology +12

EXPECTANT MANAGEMENT OF NONPALPABLE PROSTATE CANCER WITH CURATIVE INTENT: PRELIMINARY RESULTS

H. Ballentine Carter, Patrick C. Walsh, Patricia Landis et al. · The Journal of Urology · 2002 · 235 citations

Medicine, Oncology, Surgery +9